^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD45 inhibitor

    Related drugs:
    7ms
    NCI-2018-01788: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: May 2024 --> Jun 2027
    Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • Iomab-B (I-131-apamistamab)
    7ms
    Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Fred Hutchinson Cancer Center | Suspended --> Recruiting
    Enrollment open
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • sirolimus • fludarabine IV • Iomab-B (I-131-apamistamab)
    8ms
    NCI-2018-01788: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Jun 2027 --> May 2024
    Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • Iomab-B (I-131-apamistamab)
    8ms
    Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Recruiting, University of Texas Southwestern Medical Center | Not yet recruiting --> Recruiting | Trial completion date: May 2029 --> May 2030 | Trial primary completion date: May 2028 --> May 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Iomab-B (I-131-apamistamab) • apamistamab-I-131 (Iomab-ACT)
    8ms
    Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, University of Texas Southwestern Medical Center | Initiation date: Apr 2025 --> Jul 2025
    Trial initiation date
    |
    Iomab-B (I-131-apamistamab) • apamistamab-I-131 (Iomab-ACT)
    10ms
    211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia (clinicaltrials.gov)
    P1/2, N=75, Recruiting, Fred Hutchinson Cancer Center | Suspended --> Recruiting | Trial completion date: Mar 2027 --> Mar 2029 | Trial primary completion date: Jan 2023 --> Jun 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    fludarabine IV • cyclosporin A microemulsion
    11ms
    NCI-2018-01788: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Mar 2027 --> Mar 2029 | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • Iomab-B (I-131-apamistamab)
    11ms
    Study of IOMAB-ACT Followed by Yescarta for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, University of Texas Southwestern Medical Center
    New P1/2 trial
    |
    Yescarta (axicabtagene ciloleucel) • Iomab-B (I-131-apamistamab) • apamistamab-I-131 (Iomab-ACT)
    12ms
    MED20-165: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=6, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    apamistamab-I-131 (Iomab-ACT)
    over1year
    Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases (clinicaltrials.gov)
    P1/2, N=40, Suspended, Fred Hutchinson Cancer Center | Recruiting --> Suspended
    Trial suspension
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    HLA-A*02
    |
    cyclophosphamide • sirolimus • fludarabine IV • Iomab-B (I-131-apamistamab)
    almost2years
    NCI-2018-01788: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Oct 2025 --> Mar 2027 | Trial primary completion date: Jan 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • Iomab-B (I-131-apamistamab)
    2years
    CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy. (PubMed, Ann Hematol)
    Bioinformatics analysis identified genes whose expression was correlated with CD45 expression such as JAK2, ACTR2, THAP3 Serglycin, and PBX-1 genes, as well as licensed drugs (alendronate, allopurinol, and balsalazide), which could be repurposed as CD45 inhibitors which effectively increases sensitivity to cytarabine and ruxolitinib at low doses. Therefore, CD45 inhibition could be explored as a potential therapeutic partner for treatment of myeloid malignancies in combination with chemotherapy such as cytarabine especially for elderly patients and those showing chemotherapy resistance.
    Journal
    |
    JAK2 (Janus kinase 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • ACTR2 (Actin Related Protein 2)
    |
    PTPRC expression
    |
    cytarabine • Jakafi (ruxolitinib)